AtriCure (ATRC) Tops Q2 EPS by 19c; Offers Guidance

AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.11), $0.19 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $100.9 million versus the consensus estimate of $97.55 million.

GUIDANCE:

AtriCure sees FY2023 EPS of $0.92-$0.94, versus the consensus of ($1.09). AtriCure sees FY2023 revenue of $392-395 million, versus the consensus of $388.4 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c